May 15, 2012 11:04 AM | 1 min read |
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
UBS Investment Research raises its rating on Cepheid (NASDAQ: CPHD) from Neutral to Buy and lifts its price target from $44 to $45. UBS Investment Research says, "We are upgrading CPHD to Buy from Neutral, as a ~16% decline in shares since 3/26 (vs. ~5% for the S&P) has yielded an attractive buying opportunity, in our view. Overall business momentum appears solid, new product launches represent catalysts in 2H, and we view the company's profile (no exposure to NIH budgeting, relatively low sensitivity to EU macro issues) as favorable. While shares remain at a premium (EV/ '12 sales of 6.8x vs. 3.8x for CPHD'sdiagnostics peers), we believe valuation is backed by a robust growth forecast & M&A potential."CPHD closed at $37.24 on Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.